Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?

Yes- tarlatamab is a bispecific T-cell engager targeting DLL3, and thus, DLL3 expression is needed. Given the widespread expression in SCLC in approximately 90% of cases, testing for DLL3 expression prior to administering drug therapy is not required.